New research indicates that individuals who come off popular GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who halt traditional lifestyle programs.
Findings released in a leading medical journal points out that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People buying these treatments must be cognizant of the risk of rapid weight regain when the medication ends," stated expert Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight within about 18 months.
Analyzing Approaches
The analysis, which examined 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
The team point out that people who shed pounds through dieting generally have a less rapid creep back—around 100 grams monthly—after stopping.
Explaining the Fast Rebound
Experts propose the way of the injections is key to understanding the heightened weight return.
The injections copy a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement means hunger is uncontrolled, making excessive eating much more probable."
An Ongoing Disease?
The NHS suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, due to the high risk of weight regain, the therapy might need to be life-long.
This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the chronic character of obesity," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have come off the jabs describe a sudden resurgence of appetite.
"It felt as if a switch activating and I was suddenly extremely hungry," described a patient.
The struggle is compounded if individuals have not developed permanent lifestyle or habit modifications during therapy.
Widespread Interest
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is more common among women than males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while the jabs are potent tools for weight loss, they are not a permanent fix and long-term success hinges on combined behavioural changes.
